Damora Therapeutics, Inc.
NASDAQ:DMRABiotechnology
Healthcare
$22.98 +0.34%
+$0.07 today
- Market cap
- $1.42B
- Beta
- 1.48
- P/E (TTM)
- -0.1
- EPS (TTM)
- -$177.15
52W Low $2.45High $38.33
Volume 0.58M
Average 0.33M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$6.73M
FY 2025 · Annual
Investing Cash Flow
-$17.37M
FY 2025 · Annual
Financing Cash Flow
$266.84M
FY 2025 · Annual
Cash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (51.75M) | (61.62M) | (38.35M) | (21.44M) | (209.84M) |
| Depreciation & Amortization | 441K | 490K | 830K | 181K | 34K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 998K |
| Change in Working Capital | (6.62M) | 11.94M | (4.37M) | (2.67M) | 18.36M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (1.32M) | 1.82M | (1.65M) | (1.33M) | 17.27M |
| Other Working Capital | (5.3M) | 10.12M | (2.72M) | (1.34M) | 1.09M |
| Other Non-Cash Items | 5.63M | 6.27M | 4.98M | 5.3M | 183.72M |
| Operating Cash Flow | (52.31M) | (42.93M) | (36.91M) | (18.62M) | (6.73M) |
| Capital Expenditures | (223K) | (196K) | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 83K | 0 | (17.37M) |
| Purchases of Investments | (84.21M) | (44.87M) | (25.94M) | 0 | 0 |
| Sales of Investments | 36.38M | 57.45M | 48.18M | 11.65M | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (48.05M) | 12.38M | 22.33M | 11.65M | (17.37M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 507K | 2.88M | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 33K |
| Financing Cash Flow | 0 | 507K | 2.88M | 0 | 266.84M |
| Effect of Forex Changes | (663K) | 264K | 384K | (317K) | 705K |
| Net Change in Cash | (101.02M) | (29.78M) | (11.32M) | (7.29M) | 243.45M |
| Free Cash Flow | (52.53M) | (43.13M) | (36.91M) | (18.62M) | (6.73M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$209.8M
+ D&A$34.0K
+ Stock-Based Comp$998.0K
+ Deferred Tax$0
+ Working Capital$18.4M
+ Other Non-Cash$183.7M
= Operating Cash Flow-$6.7M
- Capex$0
= Free Cash Flow-$6.7M
Analysis
FY2025 free cash flow is -$6.7M. FCF conversion is 3.2% of net income. Operating cash flow was -$6.7M, with capex of $0. The largest bridge item is Other Non-Cash at $183.7M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 28, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 13, 2026 | |
| 3 | Initial statement of beneficial ownership | Aug 13, 2026 | |
| EFFECT | EFFECT filing | Aug 12, 2026 |
Does DMRA generate free cash flow?
Damora Therapeutics, Inc. (DMRA) generated -$6.73M of free cash flow in fiscal 2025.
How much operating cash flow does DMRA produce?
Operating cash flow was -$6.73M, before capital expenditures of $0.00.
Continue the stock analysis
Jump to another research area for this company.